Abstract
A recent analysis of cell-free DNA from blood samples found that ESR1 mutations are highly prevalent and associated with worse overall survival in women with advanced estrogen receptor-positive breast cancer that progressed on aromatase inhibitor therapy. The data also show that patients' mutation status may affect their response to the mTOR inhibitor everolimus.
©2016 American Association for Cancer Research.
MeSH terms
-
Androstadienes / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols
-
Breast Neoplasms / blood*
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / genetics
-
Clinical Trials, Phase III as Topic
-
Congresses as Topic
-
Estrogen Receptor alpha / blood
-
Estrogen Receptor alpha / genetics*
-
Everolimus / therapeutic use*
-
Female
-
Humans
-
Mutation
-
Treatment Outcome
Substances
-
Androstadienes
-
ESR1 protein, human
-
Estrogen Receptor alpha
-
Everolimus
-
exemestane